Novo Nordisk

Obesity rates have been skyrocketing across Africa, with one in five adults and one in 10 children were obese by the end of 2023 in 10 high-burden countries if urgent action is not taken

Novo Nordisk aims to begin the phase 3 development program for amycretin in the first quarter of 2026, targeting adults who are overweight or living with obesity.

Deep Apple will receive an upfront payment, funding for research, and milestone payments, potentially totaling US$812 million, in addition to royalties from any successful products.

The company will present 29 abstracts covering a range of studies, including trials on a higher dose of Wegovy® (semaglutide 7.2 mg) aimed at people with obesity who require greater weight loss.

Lars Fruergaard Jørgensen, who has served as CEO since January 2017, will step down from his role by mutual agreement with the Board.

Under the agreement, the two companies will initially launch four development programs focused on creating small molecule therapies that target specific GPCRs, including the GLP-1, GIP, and glucagon receptors.

In the first quarter of 2025, Wegovy sales totaled 17.36 billion Danish kroner ( U$2.64 billion) representing a 13% decline from the previous quarter and fell short of analysts’ expectations of 18.7 billion kroner (US$2.85 billion).

The REAL8 trial met its primary endpoints across the three studied conditions, marking a major step in providing effective, less burdensome treatment options for children facing growth challenges

By shifting manufacturing to the local level, Novo Nordisk aims to increase access to its life-changing medicines, serve more patients, and simultaneously support the development of local industry and workforce skills.